$17.23
+0.86 (+5.25%)
Open$16.87
Previous Close$16.37
Day High$17.46
Day Low$16.30
52W High$32.35
52W Low$13.80
Volume—
Avg Volume594.5K
Market Cap266.89M
P/E Ratio27.73
EPS$0.81
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+45.9% upside
Current
$17.23
$17.23
Target
$25.14
$25.14
$17.03
$25.14 avg
$37.02
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 64.19M | 65.56M | 69.77M |
| Net Income | 8.40M | 8.13M | 10.74M |
| Profit Margin | 13.1% | 12.4% | 15.4% |
| EBITDA | 15.55M | 13.35M | 15.74M |
| Free Cash Flow | 10.13M | 9.92M | 11.85M |
| Rev Growth | +4.7% | +24.1% | +24.2% |
| Debt/Equity | 0.89 | 0.79 | 0.95 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |